SCHEMBL379873

SCHEMBL379873

Cc1ccc(-c2csc3c(-c4cccc(S(C)(=O)=O)c4)cnc(NCc4ccccc4)c23)cc1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIP4K2C Q8TBX8 10/20 0.56
KDR P35968 3/20 0.50
AURKB Q96GD4 2/20 0.50
PTK2 Q05397 2/20 0.50
EPHB4 P54760 2/20 0.50
AURKA O14965 1/20 0.50
DYRK3 O43781 1/20 0.50
ROCK2 O75116 1/20 0.50
PRKD3 O94806 1/20 0.50
MAP4K4 O95819 1/20 0.50
ABL1 P00519 1/20 0.50
EGFR P00533 1/20 0.50
INSR P06213 1/20 0.50
FYN P06241 1/20 0.50
CSF1R P07333 1/20 0.50
LYN P07948 1/20 0.50
KIT P10721 1/20 0.50
FGFR1 P11362 1/20 0.50
FLT1 P17948 1/20 0.50
FGFR3 P22607 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL379662 0.88 CCNC (0.49) KDRAURKBAURKAROCK2MAP4K4
SCHEMBL379874 0.87 CCNC (0.47) KDRAURKBAURKAROCK2MAP4K4
SCHEMBL380180 0.85 ESR1 (0.50) KDRAURKBEPHB4FGFR1BRAF
SCHEMBL379947 0.85 KDR (0.45) PIP4K2CKDRAURKBPTK2EPHB4
SCHEMBL379184 0.85 KDR (0.49) KDRAURKBEPHB4FYNFGFR1
SCHEMBL379876 0.83 BTK (0.47) PIP4K2CKDRAURKBBRAFCYP1A2
SCHEMBL379543 0.82 THRB (0.44) KDRAURKBPTK2AURKAROCK2
SCHEMBL379469 0.82 ESR1 (0.49) KDRAURKBAURKAROCK2MAP4K4
SCHEMBL379554 0.81 BRAF (0.52) KDRAURKBCLK4BRAFUSP2
SCHEMBL379842 0.80 CYP1A2 (0.54) KDRAURKBPTK2AURKAROCK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US claimed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP claimed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US claimed
US-9216992-B2 Thieno[3,2-c]pyridine potassium channel inhibitors XENTION LIMITED (GB) 2015-12-22 US disclosed
EP-1968982-B1 THIENO (3,2-C) PYRIDINE COMPOUNDS XENTION LTD (GB) 2012-01-25 EP disclosed
EP-1968982-A2 THIENO (3,2-C) PYRIDINE COMPOUNDS Xention Discovery Ltd. (GB) 2008-09-17 EP disclosed
US-20070161672-A1 Compounds XENTION LIMITED 2007-07-12 US disclosed
WO-2007066127-A2 THIENO ( 3 , 2-C) PYRIDINE COMPOUNDS XENTION LIMITED (GB) 2007-06-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070161672-A1 Compounds KCNJ2, KCNT1, KCNT2 PIP4K2C 1388/4885KDR 2522/4885AURKB 2258/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.